Wells Fargo & Company Spero Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $429 Billion
- Q1 2025
A detailed history of Wells Fargo & Company transactions in Spero Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 200 shares of SPRO stock, worth $136. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200
Previous 200
-0.0%
Holding current value
$136
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding SPRO
# of Institutions
43Shares Held
18.2MCall Options Held
9.3KPut Options Held
100-
Anson Funds Management LP Dallas, TX7.64MShares$5.19 Million1.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.76MShares$1.2 Million0.0% of portfolio
-
Atlas Venture Associates Ix, LLC Boston, MA1.35MShares$920,24614.54% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny971KShares$660,2160.0% of portfolio
-
Alphabet Inc. Mountain View, CA890KShares$605,1850.06% of portfolio
About Spero Therapeutics, Inc.
- Ticker SPRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,067,500
- Market Cap $23.8M
- Description
- Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...